Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IDEAYA Biosciences (IDYA) Change in Account Payables (2019 - 2025)

IDEAYA Biosciences (IDYA) has disclosed Change in Account Payables for 7 consecutive years, with -$858000.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables fell 128.83% to -$858000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2025, down 67.43% year-over-year, with the annual reading at $2.7 million for FY2025, 67.43% down from the prior year.
  • Change in Account Payables hit -$858000.0 in Q4 2025 for IDEAYA Biosciences, down from $1.2 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $9.7 million in Q2 2024 to a low of -$3.9 million in Q3 2024.
  • Historically, Change in Account Payables has averaged $832100.0 across 5 years, with a median of $387000.0 in 2021.
  • Biggest five-year swings in Change in Account Payables: surged 5771.43% in 2022 and later tumbled 3675.0% in 2024.
  • Year by year, Change in Account Payables stood at -$7000.0 in 2021, then soared by 5771.43% to $397000.0 in 2022, then skyrocketed by 339.55% to $1.7 million in 2023, then soared by 70.54% to $3.0 million in 2024, then plummeted by 128.83% to -$858000.0 in 2025.
  • Business Quant data shows Change in Account Payables for IDYA at -$858000.0 in Q4 2025, $1.2 million in Q3 2025, and -$364000.0 in Q2 2025.